GLUE Dividend: Monte Rosa Therapeutics Inc Yield Insights

Income

Balance sheet

Cash flow

Annual

Quarterly

GLUE Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	181	75	0	0	0	0
Revenue Growth (YoY)	1,193%	--	--	--	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	34	43	39	35	15	4
Research & Development	138	112	103	77	57	24
Operating Expenses	173	156	143	112	72	28
Other Non Operating Income (Expenses)	--	--	--	0	0	-7
Pretax Income	21	-70	-135	-108	-73	-35
Income Tax Expense	1	2	0	--	--	--
Net Income	20	-72	-135	-108	-73	-35
Net Income Growth	-117%	-47%	25%	48%	109%	400%
Shares Outstanding (Diluted)	82.39	73.91	51.39	47.23	46.54	44.49
Shares Change (YoY)	0%	44%	9%	1%	5%	0%
EPS (Diluted)	0.25	-0.98	-2.63	-2.3	-1.59	-0.81
EPS Growth	-117%	-63%	15%	45%	96%	376%
Free Cash Flow	145	38	-62	-105	-69	-26
Free Cash Flow Per Share	1.75	0.51	-1.2	-2.22	-1.48	-0.58
Gross Margin	--	--	--	--	--	--
Operating Margin	4.41%	-108%	0%	0%	0%	0%
Profit Margin	11.04%	-96%	0%	0%	0%	0%
Free Cash Flow Margin	80.11%	50.66%	0%	0%	0%	0%
EBITDA	16	-73	-137	-109	-70	-28
EBITDA Margin	8.83%	-97.33%	0%	0%	0%	0%
D&A For EBITDA	8	8	6	3	2	0
EBIT	8	-81	-143	-112	-72	-28
EBIT Margin	4.41%	-108%	0%	0%	0%	0%
Effective Tax Rate	4.76%	-2.85%	0%	--	--	--